Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58



Cahn, Avivit, Wiviott, Stephen D, Mosenzon, Ofri, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Leiter, Lawrence A, Bhatt, Deepak L
et al (show 8 more authors) (2021) Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58. DIABETES OBESITY & METABOLISM, 23 (1). 29 - 38.

[img] Text
Cahn 10.1111_dom.14179.pdf - Accepted Version

Download (1MB) | Preview
Item Type: Article
Uncontrolled Keywords: cardiovascular disease, dapagliflozin, GLP-1 analogue, heart failure, insulin therapy, metformin
Depositing User: Symplectic Admin
Date Deposited: 15 Sep 2020 08:03
Last Modified: 10 Sep 2022 22:10
DOI: 10.1111/dom.14179
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3101247